Mycobacterium tuberculosis cytochrome P450 enzymes: A cohort of novel TB drug targets

Sean A. Hudson; Kirsty J. McLean; Andrew W. Munro; Chris Abell

doi:10.1042/BST20120062

Mycobacterium tuberculosis cytochrome P450 enzymes: A cohort of novel TB drug targets

Sean A. Hudson, Kirsty J. McLean, Andrew W. Munro, Chris Abell

Research output: Contribution to journal › Conference article › peer-review

25 Citations (Scopus)

Abstract

TB (tuberculosis) disease remains responsible for the death of over 1.5 million people each year. The alarming emergence of drug-resistant TB has sparked a critical need for new front-line TB drugs with a novel mode of action. In the present paper, we review recent genomic and biochemical evidence implicating Mycobacterium tuberculosis CYP (cytochrome P450) enzymes as exciting potential targets for new classes of anti-tuberculars. We also discuss HTS (high-throughput screening) and fragment-based drug-discovery campaigns that are being used to probe their potential druggability.

Original language	English
Pages (from-to)	573-579
Number of pages	7
Journal	Biochemical Society Transactions
Volume	40
Issue number	3
Early online date	22 May 2012
DOIs	https://doi.org/10.1042/BST20120062
Publication status	Published - 1 Jun 2012
Externally published	Yes
Event	Biochemical Society Annual Symposium: Frontiers in Biological Catalysis - Robinson College, Cambridge, United Kingdom Duration: 10 Jan 2012 → 12 Jan 2012 https://www.rsc.org/events/detail/6826/annual-symposium-frontiers-in-biological-catalysis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1042/BST20120062Licence: Unspecified

Cite this

@article{b6b62da8ee084632ae5e2cbc990b025c,

title = "Mycobacterium tuberculosis cytochrome P450 enzymes: A cohort of novel TB drug targets",

abstract = "TB (tuberculosis) disease remains responsible for the death of over 1.5 million people each year. The alarming emergence of drug-resistant TB has sparked a critical need for new front-line TB drugs with a novel mode of action. In the present paper, we review recent genomic and biochemical evidence implicating Mycobacterium tuberculosis CYP (cytochrome P450) enzymes as exciting potential targets for new classes of anti-tuberculars. We also discuss HTS (high-throughput screening) and fragment-based drug-discovery campaigns that are being used to probe their potential druggability.",

keywords = "Cytochrome P450, Drug discovery, Fragment-based drug discovery, High-throughput screening (HTS), Mycobacterium tuberculosis, Tuberculosis",

author = "Hudson, {Sean A.} and McLean, {Kirsty J.} and Munro, {Andrew W.} and Chris Abell",

year = "2012",

month = jun,

day = "1",

doi = "10.1042/BST20120062",

language = "English",

volume = "40",

pages = "573--579",

journal = "Biochemical Society Transactions",

issn = "0300-5127",

publisher = "Portland Press Ltd.",

number = "3",

note = "Biochemical Society Annual Symposium : Frontiers in Biological Catalysis ; Conference date: 10-01-2012 Through 12-01-2012",

url = "https://www.rsc.org/events/detail/6826/annual-symposium-frontiers-in-biological-catalysis",

}

TY - JOUR

T1 - Mycobacterium tuberculosis cytochrome P450 enzymes

T2 - Biochemical Society Annual Symposium

AU - Hudson, Sean A.

AU - McLean, Kirsty J.

AU - Munro, Andrew W.

AU - Abell, Chris

PY - 2012/6/1

Y1 - 2012/6/1

N2 - TB (tuberculosis) disease remains responsible for the death of over 1.5 million people each year. The alarming emergence of drug-resistant TB has sparked a critical need for new front-line TB drugs with a novel mode of action. In the present paper, we review recent genomic and biochemical evidence implicating Mycobacterium tuberculosis CYP (cytochrome P450) enzymes as exciting potential targets for new classes of anti-tuberculars. We also discuss HTS (high-throughput screening) and fragment-based drug-discovery campaigns that are being used to probe their potential druggability.

AB - TB (tuberculosis) disease remains responsible for the death of over 1.5 million people each year. The alarming emergence of drug-resistant TB has sparked a critical need for new front-line TB drugs with a novel mode of action. In the present paper, we review recent genomic and biochemical evidence implicating Mycobacterium tuberculosis CYP (cytochrome P450) enzymes as exciting potential targets for new classes of anti-tuberculars. We also discuss HTS (high-throughput screening) and fragment-based drug-discovery campaigns that are being used to probe their potential druggability.

KW - Cytochrome P450

KW - Drug discovery

KW - Fragment-based drug discovery

KW - High-throughput screening (HTS)

KW - Mycobacterium tuberculosis

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=84861490752&partnerID=8YFLogxK

U2 - 10.1042/BST20120062

DO - 10.1042/BST20120062

M3 - Conference article

C2 - 22616869

AN - SCOPUS:84861490752

VL - 40

SP - 573

EP - 579

JO - Biochemical Society Transactions

JF - Biochemical Society Transactions

SN - 0300-5127

IS - 3

Y2 - 10 January 2012 through 12 January 2012

ER -

Mycobacterium tuberculosis cytochrome P450 enzymes: A cohort of novel TB drug targets

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this